



**BASL / BSG Non-Alcoholic Fatty Liver Disease Special Interest Group  
Friday 28 February 2020**

Clark Kennedy Lecture Theatre, Innovations Centre,  
Queen Mary University of London

The following is a brief summary of the discussion and action points:

**1. Engagement**

Vanessa Hebditch told us about the fantastic work of the British Liver Trust in community engagement, activism including the 'Love Your Liver' events and the recent event in Parliament. Please look out for the BLT events in your area and support them. This is certainly an area of collaboration for colleagues to build upon. One area that was highlighted in particular is the role the BLT play in Patient and Public Involvement in research. **We were asked to contact BLT early in our grant writing to involve them in our research and also include funding lines for PPI activity in our bids.**

It was a pleasure to welcome Dr Naresh Kanumilli from the Primary Care Diabetes Society and it was very enlightening to hear about the keenness to know more about liver pathways among the PCDS members. It is also probably true to say that levels of implementation of these pathways is variable in primary care and greater collaborative working between societies is needed here. **We will ensure reciprocal invitations to upcoming meetings and education sessions to continue the dialogue.**

**2. Real world data**

Following on from Ian Rowe's engaging talk highlighting the learnings from and limitations of real world data in NAFLD/NASH, and Quentin Anstee's excellent presentation on the history, scope and potential of the European NAFLD registry, we had a discussion about the role of collecting real world data if and when new drugs receive approvals for NASH in the UK. Given the potential options and their implications, it was agreed that a **small working party** would be tasked with exploring this in more detail with a view to reporting back to the SIG at the next meeting. **Please let me know if you would like to be part of this.**

David Sheridan had asked in advance of the meeting whether the group would support an updated national survey of care standards in NAFLD along the lines of the earlier publication that David led. **The group agreed that this would be a very helpful piece of work and gave the proposal full support.**

**3. Research**

The afternoon concluded with two state of the art presentations from Massimo Pinzani and Mike Trennel. We heard about cutting edge research ranging from signalling pathways in fibrosis, through translational implications of basic science on clinical trial design and on to the growing evidence base for behaviour and lifestyle change in the management of NAFLD and NASH. Looking ahead, we will invite colleagues to **present their research and to propose collaborative research ideas** – for which there are many opportunities.